President's Column
A Time for Gratitude
October 17, 2024
It has been an enormous privilege — in fact, the highlight of my career — to serve as the 66th president of ASH. Looking ahead to 2025, ASH will be in highly capable hands with our incoming president and my dear friend Dr. Belinda Avalos.
Then and Now
Although the treatment options for older adults with leukemia still lag far behind those of younger patients, the progress made over the past two decades is unparalleled in the disease’s history.
Trainee Corner
Two hematologists who left academia to pursue careers in industry, Anita J. Kumar, MD, PhD, and Nina Shah, MD, talk about their decisions.
Blinatumomab for B-ALL?
E1910 demonstrates the immense value of randomized clinical trials in adult ALL and establishes the role of adding blinatumomab to chemotherapy during consolidation for B-ALL.
